ArticleCureus2025
Phase-Specific Resveratrol Supplementation in Distraction Osteogenesis: Supporting the Redox Environment of Bone Healing.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis experimental study investigates the correlation between resveratrol administration during the endochondral ossification process of distraction osteogenesis (DO) for the treatment of bone defects and the rate of systemic and local oxidative stress in a rabbit model of femoral DO. MATERIALS AND
methodsTwenty New Zealand white rabbits underwent femoral osteotomy and external fixation. The experimental group (n=9) received oral resveratrol (10 mg/kg/day) during the distraction phase (days 10-20), while controls (n = 9) received no antioxidant. Blood and regenerated tissues were analyzed for oxidative stress markers (8‑hydroxy‑2'-deoxyguanosine {8‑OHdG}, total antioxidant capacity {TAC}, and glutathione {GSH}) at multiple time points. Histological and immunohistochemical analyses were performed at the endpoint.
resultsResveratrol significantly reduced 8-OHdG levels and preserved TAC and GSH concentrations during the distraction phase (p<0.05). Tissue staining revealed decreased oxidative DNA damage in the regenerate zone of treated animals. No significant radiographic differences in regenerate density were observed at day 49.
conclusionsResveratrol administration during distraction mitigated oxidative stress both systemically and locally, suggesting a cytoprotective effect on bone-regenerating cells. Although radiological differences were not apparent within the study period, the redox-modulating properties of resveratrol may support more favorable regenerative outcomes over time. These findings justify further investigation into phase-specific antioxidant protocols in DO, including human application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.